NCT03968679Active, not recruiting
Lymph Drainage Mapping for Tailoring Elective Nodal Irradiation in Head and Neck Cancer
Mapping of Sentinel Lymph Node Drainage Using SPECT/CT to Tailor Highly Selective Elective Nodal Irradiation in Node-negative Neck of Patients With Head and Neck Cancer
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This study aims to explore the safety and outcome of lymph drainage mapping(LDM) to individually tailor the elective nodal irradiation (ENI) to the ipsilateral neck only. The goal is to exclude the contralateral negative neck from the irradiation fields when there is no contralateral draining sentinel node. In case contralateral lymph drainage is found on SPECT/CT, a contralateral sentinel node procedure (SNP) is performed to remove the draining node. The patient will only receive contralateral ENI if (micro/macro)metastasis are found in this contralateral sentinel node.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 27 May 2019
- Start date
- 22 Jul 2019
- Primary completion date
- 14 Jan 2026
- Lead sponsor
- The Netherlands Cancer Institute
- Diseases
- Head and neck cancer
- NCT number
- NCT03968679
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 22 Jul 2019 to the primary completion date, 14 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chemotherapy or surgery (for the present tumor), prior to inclusion
- Previous radiation treatment in the head and neck region, for any reason
- Previous neck dissection
Other illness
- Head and neck malignancies arising from skin, lip, nose, sinuses, nasopharynx, salivary glands, thyroid gland or esophagus
- Known hypersensitivity to iodine or nanocolloid injection
- Having any condition (physical, mental, sociological) that interferes with the informed consent procedure and follow-up schedules
Other
- Distant metastatic spread at the time of inclusion
- Recurrent or second primary tumor in the head and neck region
- Pregnancy or no active contraception for pre-menopausal women
Who the study is looking for
- Newly diagnosed and histopathologically proven primary HNSCC
- T1-4N0-2b
- Tumor does not cross midline
- WHO performance status 0 or 1
- Signed written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Netherlands Cancer Institute Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.